Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced the launch of Project EVEREST—a groundbreaking ...

At CTO West Coast an expert from Genentech outlined the company’s net zero goals, efforts, challenges and initiatives ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

Genentech’s short film draws on the experiences of multiple families caring for children with hemophilia A, seeking to ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

A new antibiotic that has the potential to save millions of lives has entered its last phase of human testing. Swiss ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...